Lupin launches generic TRICOR tablets
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR* tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia.
Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR* tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott's TRICOR* Tablets, 48 mg and 145 mg had sales of U5D 1.26 billion as per IMS Health, June, 2012,
Commenting on the approval, Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. & Group President, Lupin Limited said, "We are very happy to bring this product to market in the United States. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price".
Get Top 500 Company Research from acclaimed IIFL Research Team...Click Here!!!
India Infoline Research Team / 10:47, Aug 24, 2015
In spite of massive improvement in CV demand, standalone revenues for Banco Products Ltd registered muted performance with sales at Rs. 113cr in Q1 FY16.